More Than Just Risk: Genetic Testing Is Shaping Breast Cancer Treatment

https://investor.myriad.com/news-releases/news-release-detail/10806/

Myriad to Present Seven Clinical Studies at the Annual Clinical ...

Mar 25, 2014 ... Title: Determining the clinical significance of silent BRCA1 and BRCA2 sequencing variants. Presenter: Karla Bowles. Date: Friday, ...

https://investor.myriad.com/news-releases/news-release-detail/19931/

Myriad Receives FDA Approval of BRACAnalysis CDx® as ...

Oct 16, 2018 ... ... BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small ...

https://myriad.com/.../after-her-tnbc-diagnosis-stephanie-made-life-affirmin...

After Her TNBC Diagnosis, Stephanie Made Life Affirming Choices

Mar 3, 2014 ... ... BRCA1 mutation. This information further shook my optimistic attitude. I began to fear the worst – it seemed that the cards were now stacked ...

https://myriad.com/oncology/providers/

Oncology Genetic Testing | Providers - Myriad Genetics

The MyRisk Test identifies germline BRCA1/2 variants that may influence the use of targeted therapies, while minimizing variants of uncertain significance to ...

https://investor.myriad.com/news-releases/news-release-detail/11976/

Multiple Scientific Presentations at the San Antonio Breast Cancer ...

Dec 9, 2015 ... Among participants testing negative for BRCA1 and BRCA2 mutations, the myRisk test identified deleterious mutations in 14 patients, representing ...

https://investor.myriad.com/news-releases/news-release-detail/12391/

Myriad's BRACAnalysis CDx® Test Identified Patients with ...

Jun 4, 2017 ... ... BRCA1/2 mutations as determined by Myriad's BRACAnalysis CDx companion diagnostic test. The results showed that BRCA-positive patients ...

https://investor.myriad.com/news-releases/news-release-detail/20851/

News Release - Investor relations - Myriad Genetics

Nov 21, 2019 ... BRACAnalysis is a genetic test that identifies germline mutations in the BRCA1/2 genes. “We are excited that the MHLW has approved the ...

https://investor.myriad.com/news-releases/news-release-detail/21336/

Medicare Expands Coverage for BRACAnalysis® CDx in Prostate ...

Jul 31, 2020 ... Detection of deleterious or suspected deleterious germline BRCA1 and BRCA2 variants by the BRACAnalysis CDx test in ovarian cancer patients is ...

https://investor.myriad.com/news-releases/news-release-detail/20306/

Myriad's BRACAnalysis CDx® Test Successfully Identified Patients ...

... BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions ...

https://investor.myriad.com/news-releases/news-release-detail/11146/

Myriad Genetics' HRD Test Predicts Response to Platinum Therapy ...

Dec 7, 2012 ... ... recombination deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2.